Zobrazeno 1 - 10
of 125
pro vyhledávání: '"Dik J. Kwekkeboom"'
Autor:
Arthur J. A. T. Braat, Dik J. Kwekkeboom, Boen L. R. Kam, Jaap J. M. Teunissen, Wouter W. de Herder, Koen M. A. Dreijerink, Rob van Rooij, Gerard C. Krijger, Hugo W. A. M. de Jong, Maurice A. A. J. van den Bosch, Marnix G. E. H. Lam
Publikováno v:
BMC Gastroenterology, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Neuroendocrine tumours (NET) consist of a heterogeneous group of neoplasms with various organs of origin. At diagnosis 21% of the patients with a Grade 1 NET and 30% with a Grade 2 NET have distant metastases. Treatment with pepti
Externí odkaz:
https://doaj.org/article/9217df43110c46719d01e44eef0e4678
Autor:
Dik J. Kwekkeboom, Eric P. Krenning, Gaston J.H. Franssen, Casper H.J. van Eijck, Wouter W. de Herder, Richard A. Feelders, Boen L.R. Kam, Jaap J.M. Teunissen, Wouter A. van der Zwan, Tessa Brabander
Purpose: Bronchial and gastroenteropancreatic neuroendocrine tumors (NET) are slow-growing tumors, which frequently express somatostatin receptors on their cell membranes. These receptors are targets for therapy with Lutetium-177–labeled somatostat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c4612c0e165b6fe528605236248f6c1
https://doi.org/10.1158/1078-0432.c.6525275.v1
https://doi.org/10.1158/1078-0432.c.6525275.v1
Autor:
Dik J. Kwekkeboom, Eric P. Krenning, Gaston J.H. Franssen, Casper H.J. van Eijck, Wouter W. de Herder, Richard A. Feelders, Boen L.R. Kam, Jaap J.M. Teunissen, Wouter A. van der Zwan, Tessa Brabander
Supplement Table 1. A. Characteristics of the 4 patients with acute leukemia in follow-up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bac13d22837408bf49aa3d1b183f40b
https://doi.org/10.1158/1078-0432.22462970
https://doi.org/10.1158/1078-0432.22462970
Autor:
Dik J. Kwekkeboom, Eric P. Krenning, Gaston J.H. Franssen, Casper H.J. van Eijck, Wouter W. de Herder, Richard A. Feelders, Boen L.R. Kam, Jaap J.M. Teunissen, Wouter A. van der Zwan, Tessa Brabander
Supplement Figure 1. Median overall survival for patients receiving a cumulative dose of {greater than or equal to}100 mCi 177Lu-DOTATATE with a primary NET located in the midgut with and without progression at baseline.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d00c190e0f54b7ce466c4d6e8310c42d
https://doi.org/10.1158/1078-0432.22462967.v1
https://doi.org/10.1158/1078-0432.22462967.v1
Autor:
Richard P. Baum, Eric P. Krenning, Mark Kidd, Giovanni Paganelli, Stefano Severi, Anna Malczewska, Irvin M. Modlin, Wouter A. van der Zwan, Ignat Drozdov, Dik J. Kwekkeboom, Aviral Singh, Lisa Bodei
Publikováno v:
Eur J Nucl Med Mol Imaging
European Journal of Nuclear Medicine and Molecular Imaging, 47, 895-906. Springer-Verlag
European Journal of Nuclear Medicine and Molecular Imaging, 47, 895-906. Springer-Verlag
PURPOSE: Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Q
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ca03451201c668e5911cd78a1a07151
https://doi.org/10.1007/s00259-019-04601-3
https://doi.org/10.1007/s00259-019-04601-3
Autor:
Rodney J, Hicks, Dik J, Kwekkeboom, Eric, Krenning, Lisa, Bodei, Simona, Grozinsky-Glasberg, Rudolf, Arnold, Ivan, Borbath, Jaroslaw, Cwikla, Christos, Toumpanakis, Greg, Kaltsas, Philippa, Davies, Dieter, Hörsch, Eva, Tiensuu Janson, John, Ramage, B, Wiedenmann
Publikováno v:
Neuroendocrinology, 105(3), 295-309. Karger
The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fcceefd2faf2e912577e0f4897031746
https://hdl.handle.net/1765/108677
https://hdl.handle.net/1765/108677
Autor:
Eric P. Krenning, Dik J. Kwekkeboom, Wouter A. van der Zwan, Hendrik Bergsma, P. P. M. Kooij, Boen L. R. Kam, Mark Konijnenberg, Jaap J.M. Teunissen, Katya Mauff
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging
Purpose After peptide receptor radionuclide therapy (PRRT), renal toxicity may occur, particular in PRRT with 90Y-labelled somatostatin analogues. Risk factors have been identified for increased probability of developing renal toxicity after PRRT, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::776766ae61732af207604da9c3d64c79
https://doi.org/10.1007/s00259-016-3382-9
https://doi.org/10.1007/s00259-016-3382-9
Publikováno v:
Seminars in Nuclear Medicine, 46(3), 225-238. W.B. Saunders
Peptide receptor radionuclide therapy (PRRT) has been utilized for more than two decades and has been accepted as an effective therapeutic modality in the treatment of inoperable or metastatic gastroenteropancreatic neuroendocrine neoplasms (NENs) or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ee84915c58750b00762f8076296595
https://doi.org/10.1053/j.semnuclmed.2015.12.003
https://doi.org/10.1053/j.semnuclmed.2015.12.003
Autor:
Gaston J H Franssen, Kimberly Kamp, Leo J. Hofland, Roxanne C.S. van Adrichem, Richard A Feelders, Katharina Biermann, Dik J. Kwekkeboom, Carolien H M van Deurzen, Wouter W. de Herder
Publikováno v:
Neuroendocrinology, 103(5), 560-566. Karger
Background and Aims: It is unknown whether tumoral somatostatin receptor subtype 2a (sst2a) immunohistochemistry (IHC) has additional value compared to somatostatin receptor scintigraphy (SRS) uptake using OctreoScan® in predicting response to pepti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9f493af34e5fb28967d4c4684eb1060
https://pure.eur.nl/en/publications/f1cfc04a-6809-4925-afdb-8d72da5ed4b0
https://pure.eur.nl/en/publications/f1cfc04a-6809-4925-afdb-8d72da5ed4b0
Autor:
Dik J. Kwekkeboom, Casper H.J. van Eijck, Tessa Brabander, Gaston J H Franssen, Jaap J.M. Teunissen, Richard A Feelders, Wouter W. de Herder
Publikováno v:
Best Practice & Research Clinical Endocrinology & Metabolism, 30(1), 103-114. Bailliere Tindall Ltd
In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac3cb2d0b78735e83cb15a9e0b91241f
https://doi.org/10.1016/j.beem.2015.10.005
https://doi.org/10.1016/j.beem.2015.10.005